APA (7th ed.) Citation

CJ, Y., MH, C., YY, C., LY, B., JS, C., JC, H., . . . DS, C. (2026). Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: A Phase IIa trial. British journal of cancer. https://doi.org/10.1038/s41416-026-03515-w

Chicago Style (17th ed.) Citation

CJ, Yen, et al. "Efficacy and Safety of a Novel Oral Anti-vasculogenic Mimicry Agent, CVM-1118, in Advanced Well-differentiated Neuroendocrine Tumors: A Phase IIa Trial." British Journal of Cancer 2026. https://doi.org/10.1038/s41416-026-03515-w.

MLA (9th ed.) Citation

CJ, Yen, et al. "Efficacy and Safety of a Novel Oral Anti-vasculogenic Mimicry Agent, CVM-1118, in Advanced Well-differentiated Neuroendocrine Tumors: A Phase IIa Trial." British Journal of Cancer, 2026, https://doi.org/10.1038/s41416-026-03515-w.